全文获取类型
收费全文 | 1303篇 |
免费 | 116篇 |
国内免费 | 19篇 |
专业分类
儿科学 | 80篇 |
妇产科学 | 4篇 |
基础医学 | 145篇 |
口腔科学 | 144篇 |
临床医学 | 128篇 |
内科学 | 206篇 |
皮肤病学 | 80篇 |
神经病学 | 66篇 |
特种医学 | 250篇 |
外科学 | 101篇 |
综合类 | 29篇 |
预防医学 | 71篇 |
眼科学 | 16篇 |
药学 | 36篇 |
1篇 | |
肿瘤学 | 81篇 |
出版年
2023年 | 6篇 |
2022年 | 8篇 |
2021年 | 11篇 |
2020年 | 18篇 |
2019年 | 13篇 |
2018年 | 21篇 |
2017年 | 21篇 |
2016年 | 21篇 |
2015年 | 38篇 |
2014年 | 35篇 |
2013年 | 58篇 |
2012年 | 36篇 |
2011年 | 33篇 |
2010年 | 65篇 |
2009年 | 60篇 |
2008年 | 38篇 |
2007年 | 45篇 |
2006年 | 37篇 |
2005年 | 32篇 |
2004年 | 21篇 |
2003年 | 32篇 |
2002年 | 18篇 |
2001年 | 19篇 |
2000年 | 11篇 |
1999年 | 24篇 |
1998年 | 82篇 |
1997年 | 79篇 |
1996年 | 60篇 |
1995年 | 54篇 |
1994年 | 39篇 |
1993年 | 45篇 |
1992年 | 13篇 |
1991年 | 27篇 |
1990年 | 16篇 |
1989年 | 42篇 |
1988年 | 36篇 |
1987年 | 31篇 |
1986年 | 20篇 |
1985年 | 21篇 |
1984年 | 15篇 |
1983年 | 13篇 |
1982年 | 15篇 |
1981年 | 14篇 |
1980年 | 20篇 |
1978年 | 14篇 |
1977年 | 16篇 |
1976年 | 10篇 |
1975年 | 10篇 |
1972年 | 5篇 |
1969年 | 7篇 |
排序方式: 共有1438条查询结果,搜索用时 17 毫秒
101.
Lesimple T Hassel MB Gédouin D Seigneuret E Carsin B Hamlat A Riffaud L Simon H Malhaire JP Guégan Y 《Journal of neuro-oncology》2003,65(2):141-148
A phase I study was performed to determine the maximum tolerated dose and the recommended dose of continuous intravenous infusion of topotecan in combination with radiotherapy (RT) in patients with previously untreated glioblastoma multiforme (GBM). Twenty patients with histologically proven GBM and 1 with rhabdoid tumor were enrolled. After surgery or stereotactic biopsy, patients received cranial RT (60 Gy/30 fractions/40 days) and 3 cycles of topotecan as continuous infusion (CIV) from day 1 to 5 on weeks 1, 3, and 5 during RT. The dose of topotecan was escalated from 0.6 to 1.0 mg/m2/day. Four dose levels were tested. One grade 4 thrombocytopenia was seen at level 1 (topotecan dose 0.6 mg/m2/day; 6 patients). No dose-limiting toxicity was seen at level 2 (0.8 mg/m2/day; 3 patients) or an intermediate level of 2 bis (0.9 mg/m2/day; 6 patients). Six patients were included at level 3 (1.0 mg/m2/day), 4 of whom experienced dose-limiting toxicities, including 3 episodes of grade 4 thrombocytopenia, 1 platelet transfusion, 1 febrile neutropenia, and 1 grade 4 neutropenia of more than 7 days. Eighty percent of patients with GBM were alive at 12 months. The dose-limiting toxicity of topotecan administered as CIV for 5 days every 2 weeks is hematological. The maximum tolerated dose is 1.0 mg/m2/day and the recommended dose is 0.9 mg/m2/day. A phase II trial using the recommended dose of topotecan is ongoing. 相似文献
102.
Frappaz D Chinot O Bataillard A Ben Hassel M Capelle L Chanalet S Chatel M Figarella-Branger D Guegan Y Guyotat J Khé HX Jouanneau E Keime-Guibert F Laforêt C Linassier C Loiseau H Menel P Rousmans S Sanson M Sunyach MP 《Bulletin du cancer》2003,90(10):873-886
CONTEXT: The "Standards, Options and Recommendations" (SOR) project, which started in 1993, is a collaboration between the Federation of French Cancer Centers (FNCLCC), the 20 French Regional Cancer Centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. OBJECTIVE: To define clinical practice guidelines for the management of adult patients with intracranial glioma in collaboration with the Association of French-speaking Neuro-oncologists (Anocef) and the French society of neurosurgeons (SNCLF). These recommendations cover diagnosis, classification, treatment and follow-up of patients with these tumors. METHOD: The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts who define the CPGs according to the definitions of the Standards, Options and Recommendations project. Once the guidelines has been defined, the document is submitted for review by independent reviewers. RESULTS: This article is a summary version of the full document presenting the clinical practice guidelines with algorithms. The main recommendations concern the place of the surgery, radiotherapy, chemiotherapy, imagery and concomitant medical treatments in the specific treatment strategy of grade III and IV glioma, grade II glioma, gliomatosis cerebri, pilocytic astrocytoma, subependymoma, xanthoastrocytoma, intracranial ependymoma and brain stem glioma. 相似文献
103.
<Emphasis Type="Italic">BRCA1</Emphasis> and <Emphasis Type="Italic">BRCA2</Emphasis> mutations in a population-based study of male breast cancer
下载免费PDF全文
![点击此处可从《Breast cancer research : BCR》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Victoria?M?Basham Julian?M?Lipscombe Joanna?M?Ward Simon?A?Gayther Bruce?AJ?Ponder Douglas?F?Easton Paul?DP?PharoahEmail author 《Breast cancer research : BCR》2001,4(1):R2
Background
The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear.Methods
We have carried out a population-based study of 94 MBC cases collected in the UK. We screened genomic DNA for mutations in BRCA1 and BRCA2 and used family history data from these cases to calculate the risk of breast cancer to female relatives of MBC cases. We also estimated the contribution of BRCA1 and BRCA2 to this risk.Results
Nineteen cases (20%) reported a first-degree relative with breast cancer, of whom seven also had an affected second-degree relative. The breast cancer risk in female first-degree relatives was 2.4 times (95% confidence interval [CI] = 1.4–4.0) the risk in the general population. No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2. Allowing for a mutation detection sensitivity frequency of 70%, the carrier frequency for BRCA2 mutations was 8% (95% CI = 3–19). All the mutation carriers had a family history of breast, ovarian, prostate or pancreatic cancer. However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives.Conclusion
These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found.104.
Marrow graft failure observed in association with histocompatibility differences between donor and recipient is often attributed to rejection mediated by host-derived cytolytic T lymphocytes. The data presented in this report indicate that persistent host antibodies specific for donor antigen may also mediate graft failure, either by antibody-dependent cell-mediated cytotoxicity (ADCC), or complement- mediated cytotoxicity. In the case of HLA Class I disparity, where all donor cells express the target antigen, the presence of alpha-donor antibody was associated with complete graft failure and death. In the case of ABO blood group antigen disparity, the presence of alpha-donor antibody resulted in erythroid hypoplasia. The latter cases proved informative insofar as they established that host antibodies could persist for more than 18 months after chemoradiotherapy and impair marrow function. 相似文献
105.
106.
R Mahajan I Kaur AJ Kanwar 《Journal of the European Academy of Dermatology and Venereology》2010,24(5):595-600
Background Psoriasis is a chronic, recurring inflammatory disease affecting the skin, joints and nails that has a significant negative impact on the quality of life. Efficacy of combination of methotrexate/narrowband ultraviolet B (NBUVB) phototherapy in the treatment of psoriasis has been rarely assessed. Objectives To compare the efficacy of methotrexate/NBUVB phototherapy combination vs. NBUVB phototherapy in the treatment of chronic plaque psoriasis. Methods Forty patients with chronic plaque‐type psoriasis (body surface area involvement >10%) were randomized to receive either methotrexate/NBUVB phototherapy (group A) or placebo/NBUVB phototherapy (group B). End point of treatment was 75% reduction in Psoriasis Area and Severity Index (PASI) Score or upto 6 months, whichever was earlier. Patients were then followed up for a period of 12 weeks for assessment of relapse. Results Of 40 patients, 37 completed the treatment period and 29 both the treatment period and follow‐up. PASI 75 was achieved in 19/20 patients in group A and 14/20 patients in group B (P < 0.04). The mean number of weeks(P = 0.001), the mean cumulative dose of NBUVB (P = 0.001) and the mean number of phototherapy sessions (P = 0.0001) required to achieve PASI 75 were significantly less in group A compared with group B. There was no significant difference in the number of patients who relapsed during the follow‐up period (P = 0.68). Conclusion Combination of methotrexate and NBUVB phototherapy provides more rapid clinical improvement compared with NBUVB monotherapy in the treatment for chronic plaque‐type psoriasis. 相似文献
107.
108.
AJ Phillips 《Clinical & experimental optometry》1989,72(2):32-34
A patient with severe ocular albinism was fitted with a prosthetic soft contact lens which improved both photophobic symptoms and facial cosmesis. 相似文献
109.
110.
Aoki S; Okada Y; Nishimura K; Barkovich AJ; Kjos BO; Brasch RC; Norman D 《Radiology》1989,172(2):381-385
Magnetic resonance (MR) images of the brain in 285 patients between the ages of 2 and 25 years were retrospectively studied to determine the appearance of brain iron accumulation. The globus pallidus, red nucleus, substantia nigra, and dentate nucleus were evaluated with long TR/TE (repetition time/echo time) spin-echo sequences and staged. All four regions in most patients were initially hyperintense compared with white matter (stage I) before becoming isointense (stage II) and subsequently hypointense (stage III). The globus pallidus was the first to reach stage III, the red nucleus and substantia nigra were next, and the dentate nucleus was last. In general, decreased signal intensity (stage III) was not seen in these regions in patients less than 10 years old; in most patients it was seen by age 25 years. The dentate nucleus decreased in signal intensity more slowly and inconsistently; only one-third of patients had reached stage III by age 25 years. The temporal sequence of normal iron deposition as detected with MR imaging is helpful not only in the diagnosis of known iron-deposition diseases but also in the detection of iron-related pathologic changes. 相似文献